We compared antibody responses of HIV-infected young women to the human papillomavirus (HPV) 6, 11, 16, and 18 vaccine using total immunoglobulin (Ig) G Luminex immunoassay (LIA) and competitive Luminex immunoassay (cLIA) assays. HPV18 seropositivity after HPV vaccination as measured with IgG LIA remained high (98%) 48 weeks after vaccination, in contrast with seropositivity as measured with cLIA (73%). Seropositivity rates at week 48 as measured by both IgG LIA and cLIA remained high for HPV6, 11, and 16 (93.5%-100%). These results suggest that the lower rate of seropositivity to HPV18 when cLIA vs. IgG LIA is used is a function of the assay and does not imply lower vaccine immunogenicity.
INTRODUCTION
The quadrivalent human papillomavirus (HPV) vaccine, which is comprised virus-like particles (VLPs) made from the L1 major capsid protein of HPV6, 11, 16, and 18, induces a complex polyclonal antibody response directed against specific conformational and linear epitopes on the VLP. 1, 2 A number of studies have demonstrated the importance of neutralizing antibodies in protection from infection. [2] [3] [4] [5] Although the antibody threshold that correlates with protection against HPV infection or disease is unknown, clinical trials have demonstrated that vaccination induces robust immune responses and is highly effective in preventing vaccine-type anogenital precancers. 6, 7 HIV-infected women are at a significantly higher risk than HIV-uninfected women for persistent HPV infection and progression to cervical precancers and invasive cervical cancer; in addition, the incidence of cervical cancer increases with more severe immunosuppression. 8, 9 HPV vaccine trials among HIV-infected young women and men demonstrated that HPV type-specific immune responses to vaccination are generally robust. [10] [11] [12] [13] [14] [15] [16] However, studies have demonstrated substantially lower seropositivity rates for HPV18 compared with HPV6, 11, and 16. In one study, 32.4% of those not on antiretroviral therapy (ART) and 13.3% of those on ART became (or remained) seronegative for HPV18 at 48 weeks after vaccination. 12 In addition, Kojic et al 14 reported lower seropositivity rates in women with higher HIV viral load and/or a lower CD4 count, whereas Kahn et al 12 reported lower seropositivity rates among those not on ART vs. those on ART.
The finding of a decline over time in HPV18 seropositivity in HIV-infected young women raises concern about the long-term efficacy of vaccination and breakthrough cases of HPV18-related cancers. However, trials of the quadrivalent vaccine in HIV-uninfected women demonstrated that efficacy was sustained despite a decrease in HPV18 immune titers, raising the possibility that an explanation for waning immunity is low sensitivity of the assay for detecting antibodies to HPV18 important for protection against infection. [17] [18] [19] In clinical trials of the quadrivalent vaccine, antibodies to the HPV L1 VLPs were measured using a competitive Luminex immunoassay (cLIA). 20 This typespecific assay simultaneously evaluates the antibody response to a unique conformational, neutralizing epitope on each of the 4 HPV types that comprise the vaccine, measuring a restricted anti-VLP HPV neutralizing response which is one component of the total immune response to vaccination. 21 The assay is highly type specific, allows for immune responses to multiple VLPs to be evaluated at the same time, and enables high throughput processing. 22 However, it measures only a subset of neutralizing antibodies that compete with the specific monoclonal antibody for VLP surface binding. It therefore underrepresents the complete VLP-induced protective antibody response elicited by vaccination with L1 VLPs: it is likely that many other antibodies, some neutralizing, are produced by vaccination but not measured by the cLIA. 21, 22 Furthermore, vaccination with L1 VLPs may not elicit identical immune responses in all individuals: some women may make efficient, neutralizing antibodies to epitopes on HPV18 VLPs that differ from the HPV18 type-specific epitope measured in the HPV18 cLIA. This may explain the decline in HPV18 antibodies in clinical trials. 21 It is difficult to determine a cLIA level that correlates with vaccine efficacy because despite the decrease in antibody titers after vaccination, the efficacy of the quadrivalent HPV vaccine remains high with very few breakthrough cases of HPV6-, 11-, 16-, or 18-associated disease. 23 Thus, the ability of the HPV cLIA to measure a long-term protective antibody response in women may be limited.
By contrast to the cLIA, the total immunoglobulin (Ig) G LIA measures total IgG antibody binding to HPV VLPs and provides a more general measure of the humoral immune response to vaccination. 24 Compared with the cLIA, the total IgG is a more sensitive assay that measures a broader subset of the total immune response to vaccination. This assay captures VLP-binding antibodies to HPV type-common epitopes, HPV type-specific epitopes, neutralizing epitopes, nonneutralizing epitopes, linear epitopes, and conformational epitopes. 21 Data comparing the changes in seropositivity using the HPV18 cLIA and the total IgG LIA in HIV-infected women will be helpful in increasing our understanding of the immune response to HPV vaccines in HIV-infected individuals, clarifying the extent and duration of the immune response to vaccination, guiding clinical practice (eg, whether a fourth vaccine dose is needed in HIV-infected individuals), understanding the limitations and benefits of different immunoassays, and understanding the ability of assays to define an immune correlate of protection if breakthrough cases occur after vaccination. 21, 22 Therefore, the aim of this study was to compare the changes in antibody response over time of HIVinfected young women to the quadrivalent HPV6, 11, 16, and 18 L1 VLP vaccine using total IgG LIA and cLIA assays, 4 and 24 weeks after the third vaccine dose. Antibody responses were measured using geometric mean titers (GMTs) and seropositivity rates. Our hypothesis was that total IgG responses would remain high, with a seropositivity rate .90%, 24 weeks after the third vaccine dose among HIV-infected young women who received all 3 vaccine doses within the recommended timeframe.
METHODS
Participants were HIV-infected young women 18-23 years of age who had participated in a clinical trial of the quadrivalent HPV vaccine. Details of study recruitment, procedures, and methodology are available in a previously published article. 12 Stored sera from women enrolled in the original study and already tested for cLIA were retested for total IgG LIA at 4 and 24 weeks after the third vaccination, corresponding to study weeks 28 and 48, respectively. Immunogenicity analyses were performed for subjects (N = 76) who received 3 doses of the quadrivalent vaccine within the study windows and had sera available at 28 and 48 weeks and who were seronegative and polymerase chain reaction negative at baseline and polymerase chain reaction negative through month 7 to the appropriate HPV type(s).
We determined the proportion of participants seropositive for HPV6, 11, 16, and 18, as measured by total cLIA and total IgG LIA at week 28 (4 weeks after the third vaccine dose) and week 48 (24 weeks after the third vaccine dose). The assay has been standardized and validated for measurements of HPV antibody responses. 21 Serostatus cutoffs for cLIA were HPV6 (20 mMU/mL), HPV11 (16 mMU/mL), HPV16 (20 mMU/mL), and HPV18 (24 mMU/mL), and for total IgG were HPV6 (15 mMU/mL), HPV11 (15 mMU/mL), HPV16 (7 mMU/mL), and HPV18 (10 mMU/mL). We also determined the GMTs for total IgG and cLIA GMTs at weeks 28 and 48. Stratified analyses were conducted by ART status. Of note, GMTs cannot be compared between HPV types because they are standardized differently.
A McNemar test for paired data was used to compare seropositivity as measured by total IgG LIA and cLIA for each HPV type at weeks 28 and 48. Analyses were conducted for all participants and stratified by ART status. Because GMTs are not comparable for total IgG and cLIA, as one assay measures general antibody binding to the VLP and the other measures competitive antibody binding to a specific neutralizing epitope, 21 univariable analyses comparing GMTs would not be meaningful and were not conducted.
RESULTS
Baseline demographic characteristics of participants were reported in detail in a previous article 12 ; briefly, the mean age of participants was 21.5 years (SD 2.1 years), 76.3% were black/African American, 18.4% were Hispanic, 30% were taking antiretrovirals, 98.7% had a CD4 + T-cell count $350 cells/mm 3 , and 38.2% had an HIV viral load ,400 copies/mL. Seropositivity rates and GMTs obtained by IgG LIA and cLIA testing are shown in the Table 1 . Seropositivity rates across all HPV serotypes at 28 and 48 weeks ranged from 88.2% to 100% using the total IgG LIA and from 72.7% to 100% using the cLIA assay. Seropositivity rates for all 4 serotypes at 28 weeks and for all serotypes except HPV18 at 48 weeks were similar when measured using the total IgG LIA vs. the cLIA assay. Seropositivity rates for HPV18 were substantially higher at 48 weeks when measured using IgG vs. cLIA for all participants (98.1% vs. 73.1%), those on ART (94.7% vs. 73.7%), and those not on ART (100% vs. 72.7%). However, the only statistically significant difference was for the group that included all participants at 48 weeks (P = 0.0002). Seropositivity rates within a given assay were similar in those taking vs. not taking ART.
GMTs were robust when measured by total IgG and cLIA; as the assays represent distinct measurements of HPV
DISCUSSION
In this study, we found that among HIV-infected young women, HPV18 seropositivity rates after HPV vaccination as measured with IgG LIA remained high (98%) 24 weeks after the third vaccine dose, in contrast with seropositivity rates as measured with cLIA (73%). These results are similar to those reported in healthy women in whom seropositivity to HPV18 measured by total IgG LIA was approximately 97% at month 48 after vaccination. 21 Nygard et al examined seropositivity rates in healthy women 9 years after vaccination and found that 91.4% remained seropositive to HPV18 when measured by total IgG LIA. 25 However, seropositivity rates were lower for all 4 HPV types as measured with cLIA among women with advanced compared with less advanced HIV disease, suggesting the importance of HPV vaccination before CD4 T-cell decline. 14 Given that HIV-infected women are at a substantially increased risk of HPV-related cancers, 8, 9 it is encouraging that seropositivity rates in this study, as measured by total IgG LIA, are similar to those in HIV-uninfected women in the same age group. Our results and those of others suggest that the quadrivalent HPV vaccine elicits a robust and sustainable immunologic response and are consistent with observations that the vaccine provides sustained protection against precancers and cancers. In healthy women, protection has been demonstrated through at least 8 years after vaccination. 17 Data comparing the HPV18 cLIA and total IgG LIA in HIV-infected women are helpful in understanding the limitations and benefits of different immunoassays to measure vaccine response. 22 As noted by Nygard et al, if the specific neutralizing epitope used by the cLIA is highly immunodominant, then antibody responses are long lasting; however, if the specific neutralizing epitope is less immunodominant, then the loss of antibodies over time does not reflect loss of protection. This is supported by a study conducted by Brown et al, in which the investigators compared serologic responses to the quadrivalent HPV vaccine using 3 assays: cLIA, total IgG LIA, and a pseudovirion-based neutralization assay (PBNA). The investigators found that for both HPV16 and HPV18, the cLIA, IgG, and PBNA assays were highly correlated. The positivity rates and correlation between the IgG and PBNA in sera that were negative by cLIA confirmed the presence of neutralizing antibody in the cLIA HPV18-negative samples. The authors concluded that both the cLIA and IgG accurately measure neutralizing antibody against HPV16 and HPV18 L1 VLPs. 26 It should be noted that the total IgG immunoassay is not a functional assay in that it measures all IgG binding to the VLP regardless of the protective potential of that antibody. The total IgG provides a broader measure of the immune response and is more sensitive, but less specific. 21 Therefore, the IgG LIA may overestimate the level of protective antibodies generated by vaccination. Some have proposed that the cLIA, with its high specificity, may be most appropriate for assessing baseline immune status, whereas the total IgG, with its high sensitivity, may be most appropriate for assessing the vaccineinduced immune response over time. 21 In addition, it is possible that the higher seropositivity rates for HPV18 when using the LIA were because of HPV16-specific antibodies. However, the correlated neutralization assay results have demonstrated that the LIA antibodies include HPV typespecific neutralizing antibodies. 26 In conclusion, the results of this study suggest that the lower rate of seropositivity to HPV18 when cLIA vs. IgG LIA is used is a function of the assay and does not imply lower inherent immunogenicity of the vaccine against HPV18 or lack of protection against infection in HIV-infected young women. Long-term clinical observation after HPV vaccination will be important to monitor for breakthrough cases of HPV-related cancers.
